Market Overview

Asia-Pacific PDX Models Market 2018-2025 - Increasing Demand for Humanized PDX Models - ResearchAndMarkets.com

Share:

The "Asia-Pacific
PDX Models Market - Companies Profiles, Size, Share, Growth, Trends and
Forecast to 2025"
report has been added to ResearchAndMarkets.com's
offering.

Asia-Pacific PDX models market is estimated to grow with a healthy CAGR
in the forecast period 2018 to 2025.

Prominent factors driving the growth of this market consist of rising
number of pharmaceutical R&D activities in cancer research, advantages
offered by PDX models offer compared with the classic approach, rising
need for personalized medicine and increasing support for cancer
research activities from government and non-government organization.

The Asia Pacific PDX models market is segmented based on type into two
notable segments; mice models and rat models. In 2018, mice models
segment is valued to rule with the highest market share 2025.

The Asia Pacific PDX models market is segmented in tumor type categories
into six notable segments; respiratory tumor models, urological tumor
models, gastrointestinal tumor models, hematological tumor models,
gynecological tumor models and others. In 2018, respiratory tumor models
segment is valued to rule with the highest market shares by 2025, rising
at the highest CAGR.

The Asia Pacific PDX models market is segmented in application into
preclinical drug development and oncology research and biomarker
analysis. In 2018, preclinical drug development and oncology research
segment is valued to rule with highest market shares and rising at the
highest CAGR.

The Asia Pacific PDX models market is segmented in end user into
contract research organization (CRO), academic and research institutions
and pharmaceutical and biotechnology companies. In 2018, contract
research organization (CRO) segment is valued to rule with highest
market shares and rising at the highest CAGR.

Market Dynamics

Drivers

  • Rising Number of Pharmaceutical R&D Activities in Cancer Research
  • PDX Models Offer Advantages as Compared with the Classic Approach
  • Rising Need for Personalized Medicine
  • Increasing Support for Cancer Research Activities from Government &
    Non-Government Organization

Restraints

  • High Cost of PDX Models
  • Strict Regulation with Respect to the Utilization of Animal Models in
    Cancer Research

Opportunities

  • Increasing Demand for Humanized PDX Models

Challenges

  • Limitations of PDX Models

Companies Profiled

  • Crown Bioscience Inc.
  • The Jackson Laboratory
  • Champion Oncology Inc.
  • Charles River
  • Oncodesign
  • Wuxi AppTec
  • Horizon Discovery Group PLC
  • Pharmatest Services
  • Hera Biolabs
  • EPO Berlin-Buch GmbH
  • Xentech
  • Urolead
  • Creative Animodel
  • EUROPDX
  • MI Bioresearch Inc.
  • Aragen Bioscience

For more information about this report visit https://www.researchandmarkets.com/research/647q8g/asiapacific_pdx?w=4

View Comments and Join the Discussion!